Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy

Author:

Barelkowski TomaszORCID,Wust Peter,Kaul David,Zschaeck Sebastian,Wlodarczyk Waldemar,Budach Volker,Ghadjar Pirus,Beck Marcus

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology, Nuclear Medicine and imaging

Reference24 articles.

1. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, Protec TSG (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220

2. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310–1317. https://doi.org/10.1016/j.ijrobp.2010.01.006

3. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988. https://doi.org/10.1016/j.ijrobp.2008.02.073

4. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5‑year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063. https://doi.org/10.1016/j.ijrobp.2010.03.049

5. Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ (2016) Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3‑dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer 122(13):2004–2011. https://doi.org/10.1002/cncr.29983

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3